New hope for cancer patients: drug may cut steroid need for immunotherapy side effect
NCT ID NCT06037811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug adalimumab can help people with arthritis caused by cancer immunotherapy use less steroids. About 30 adults will be randomly assigned to receive either adalimumab or standard steroid treatment. The goal is to see if adalimumab can control arthritis symptoms and reduce the need for steroids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-RELATED ADVERSE EVENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Joseph's Health Care
RECRUITINGLondon, Ontario, N6A 4V2, Canada
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to tame liver side effects of cancer immunotherapy
- Ultrasound may solve arthritis diagnosis puzzle
- New combo aims to boost immunotherapy in elderly melanoma patients
- Robot-Assisted knee surgery: which implant is better?
- New surgical wash aims to cut joint infection risk in 7,600 replacement patients
- Scientists analyze genetic markers in stored samples to boost personalized medicine